Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Arushi Gahlot Saini
Observed names:
Arushi Saini,
Saini, Arushi,
Saini, Arushi Gahlot
Institution:
Post Graduate Institute of Medical Education and Research
Observed institutions:
Georgia Institute of Technology,
Dana-Farber Cancer Institute,
Post Graduate Institute of Medical Education and Research
ORCID:
0000-0003-1917-4468
Observed ORCID:
0000-0003-1917-4468
OpenAlex ID:
A5081714679
Glyceraldehyde-3-phosphate dehydrogenase is a chaperone that allocates labile heme in cells
2018
·
Elizabeth A. Sweeny
, Anuradha Bharara Singh
, et al.
·
Journal of Biological Chemistry
·
127
Mitochondrial–nuclear heme trafficking in budding yeast is regulated by GTPases that control mitochondrial dynamics and ER contact sites
2020
·
Osiris Martinez-Guzman
, Mathilda M. Willoughby
, et al.
·
Journal of Cell Science
·
48
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
2025
·
Seshiru Nakazawa
, Federica Pecci
, et al.
·
Cancer Discovery
·
9
The heme biosynthetic enzyme, 5-aminolevulinic acid synthase (ALAS), and GTPases in control of mitochondrial dynamics and ER contact sites, regulate heme mobilization to the nucleus
2019
·
Osiris Martinez-Guzman
, Mathilda M. Willoughby
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
1
PDF
Engineering immune cells as dynamic therapies: An evolution-guided framework for temporally programmed CAR T cells
2026
·
Arushi Saini
·
Journal of High School Science
PDF
The Hidden Culprit in Optic Neuritis: Mitochondrial Complex I Deficiency Due to a Novel NDUFS1 Mutation
2026
·
Prabhjit Kaur
, Arushi Saini
, et al.
·
Journal of Neuro-Ophthalmology
Supplementary Appendix from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
2025
·
Seshiru Nakazawa
, Federica Pecci
, et al.
PDF
Supplementary Tables S1-S6 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
2025
·
Seshiru Nakazawa
, Federica Pecci
, et al.
PDF
Data from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
2025
·
Seshiru Nakazawa
, Federica Pecci
, et al.
Supplementary Figures S1-S9 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
2025
·
Seshiru Nakazawa
, Federica Pecci
, et al.
PDF
Supplementary Methods from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
2025
·
Seshiru Nakazawa
, Federica Pecci
, et al.
Show more works
View as search
Works count:
22
Citation count:
184
H-index:
3
I10-index:
2
Year
Topic
Type
